ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.750,05
0,40%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. AMEX
  6. Biosante Pharmaceuticals (BPA)

  7. Biosante Pharmaceuticals (BPA) News

BPA

Biosante Pharma (BPA)

Biosante Pharmaceuticals
Von:
Sortieren nach:
 Showing the most relevant articles for your search:AMEX:BPA
DatumZeitQuelleÜberschriftSymbolFirma
31/10/200722h21Edgar (US Regulatory)Biosante Pharmaceuticals Inc - Amended Securities Registration (section 12(b)) (8-A12B/A)AMEX:BPABiosante Pharmaceuticals
24/10/200717h23Edgar (US Regulatory)Biosante Pharmaceuticals Inc - Current report filing (8-K)AMEX:BPABiosante Pharmaceuticals
24/10/200717h23Edgar (US Regulatory)Biosante Pharmaceuticals Inc - Current report filingAMEX:BPABiosante Pharmaceuticals
24/10/200717h23Edgar (US Regulatory)Biosante Pharmaceuticals Inc - Current report filingAMEX:BPABiosante Pharmaceuticals
24/09/200719h57PR Newswire (US)WallSt.net Announces Upcoming Interview with CEO of BioSante PharmaceuticalsAMEX:BPABiosante Pharmaceuticals
14/08/200722h15Business WireBioSante Pharmaceuticals Reports Second Quarter 2007 Financial ResultsAMEX:BPABiosante Pharmaceuticals
08/08/200714h00Business WireBioSante Pharmaceuticals to Present at Upcoming ConferencesAMEX:BPABiosante Pharmaceuticals
25/07/200714h00Business WireBioSante Pharmaceuticals Announces Positive Results for its CaP Technology for Use in Aesthetic MedicineAMEX:BPABiosante Pharmaceuticals
11/07/200714h00Business WireBioSante Pharmaceuticals Announces New Findings for Potential Bird Flu VaccineAMEX:BPABiosante Pharmaceuticals
10/07/200713h00PR Newswire (US)WallSt.net (www.wallst.net ) Updates the Investment Community Through All-New Interviews with BPA, PPCO and NVAXAMEX:BPABiosante Pharmaceuticals
28/06/200713h00Business WireBioSante Pharmaceuticals, Inc. Joins Russell Microcap IndexAMEX:BPABiosante Pharmaceuticals
19/06/200714h00Business WireBioSante Pharmaceuticals Announces Oral Contraceptive Phase II Study InitiationAMEX:BPABiosante Pharmaceuticals
14/06/200714h00Business WireBioSante Pharmaceuticals Completes $18.3 Million Private Placement of Common StockAMEX:BPABiosante Pharmaceuticals
13/06/200714h45PR Newswire (US)Bradley Pharmaceuticals Announces Launch of Elestrin(TM)AMEX:BPABiosante Pharmaceuticals
30/05/200715h12Business WireBioSante Pharmaceuticals to Present at Upcoming ConferencesAMEX:BPABiosante Pharmaceuticals
25/05/200715h26Business WireBioSante Pharmaceuticals Announces $16.5 Million Private Placement of Common StockAMEX:BPABiosante Pharmaceuticals
16/05/200714h00Business WireBioSante Pharmaceuticals to Present at Upcoming ConferencesAMEX:BPABiosante Pharmaceuticals
07/05/200714h00Business WireBioSante Pharmaceuticals Signs Oral Contraceptive License with Pantarhei BioscienceAMEX:BPABiosante Pharmaceuticals
04/05/200714h45PR Newswire (US)Bradley Pharmaceuticals to Preview New Products at ACOG MeetingAMEX:BPABiosante Pharmaceuticals
02/05/200713h45Business WireBioSante Pharmaceuticals to Present at Upcoming ConferencesAMEX:BPABiosante Pharmaceuticals
01/05/200723h00Business WireBioSante Pharmaceuticals Reports First Quarter 2007 Financial ResultsAMEX:BPABiosante Pharmaceuticals
11/04/200714h45PR Newswire (US)Bradley Pharmaceuticals' Elestrin(TM) Receives New Patent to 2022AMEX:BPABiosante Pharmaceuticals
10/04/200714h00Business WireBioSante Pharmaceuticals Announces Issuance of New Patent Covering Elestrin(TM) and LibiGel(R)AMEX:BPABiosante Pharmaceuticals
02/04/200720h09PR Newswire (US)Dawson James Securities Reiterates Strong Buy Recommendation on Antares Pharma (Amex: AIS) with $4.00 Price TargetAMEX:BPABiosante Pharmaceuticals
26/03/200713h30Business WireBioSante Pharmaceuticals Receives Milestone Payment from Bradley PharmaceuticalsAMEX:BPABiosante Pharmaceuticals
08/03/200722h34Business WireBioSante Pharmaceuticals Reports Net Profit of $2.8 million for 2006 And Investor Conference CallAMEX:BPABiosante Pharmaceuticals
08/03/200714h00Business WireBioSante Pharmaceuticals to Present at Upcoming ConferencesAMEX:BPABiosante Pharmaceuticals
30/01/200714h00Business WireBioSante Pharmaceuticals Announces Positive Bird Flu Results Using Proprietary Vaccine Adjuvant in Pre-Clinical StudyAMEX:BPABiosante Pharmaceuticals
16/01/200715h00Business WireStephen M. Simes, President and CEO of BioSante Pharmaceuticals, Inc., Talks to The Wall Street TranscriptAMEX:BPABiosante Pharmaceuticals
19/12/200613h45PR Newswire (US)Bradley Pharmaceuticals Announces FDA Approval of Elestrin(TM) (estradiol gel 0.06%)AMEX:BPABiosante Pharmaceuticals
 Showing the most relevant articles for your search:AMEX:BPA

Kürzlich von Ihnen besucht

DBI
SDXP
SDAX
PM
XAUUSD
Gold vs US Dollar
COIN
ETHUSD
Ethereum
NASDAQ
AMZN
Amazon.com
CCOM
US100
US Tech 100
AMEX
XLV
Health Care Select Sector
TG
ALV
Allianz
FX
EURJPY
Euro vs Yen
COIN
BTCUSD
Bitcoin
NYSE
XOM
Exxon Mobil
TG
CBK
Commerzbank
DBI
MDAX
MDAX
TG
TUI1
Tui
NASDAQ
AAPL
Apple
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten